Is lorlatinib covered by medical insurance? How much does it cost?

Lorlatinib (Lorlatinib) is a third-generation tyrosine kinase inhibitor (TKI), mainly used to treat ALK (anaplastic lymphoma kinase) and ROS1(C-rosproto-oncogene1)-positive non-small cell lung cancer (NSCLC). It can effectively target the drug-resistant mutations generated after treatment with previous generation TKIs. It also has strong blood-brain barrier penetration ability and has a significant control effect on brain metastases. Lorlatinib improves patient survival by inhibiting the growth and spread of tumor cells and is one of the important treatment options for advanced lung cancer.

Larlatinib has been approved for marketing in China and has been successfully included in the national medical insurance directory. After being included in medical insurance, its price has dropped significantly, reducing the financial burden on patients. Currently, through medical insurance reimbursement, patients' average monthly out-of-pocket expenses are about 10,000 to 20,000 yuan. The specific expenses vary due to different reimbursement ratios and regional policies. For medical insurance coverage and specific reimbursement amounts, it is recommended that patients consult the local medical insurance department or hospital pharmacy to obtain accurate price information.

In the international market, there are significant differences in the price of lorlatinib. The price of original drugs in Türkiye is relatively low, with a monthly cost of about more than 7,000 yuan; the price of original drugs in Hong Kong, China, is relatively high, up to about 30,000 yuan. In addition, generic drugs produced in Laos and Bangladesh have attracted attention because of their low prices, which usually range from more than one thousand yuan to several thousand yuan. The ingredients of these generic drugs are basically the same as the original drugs, but the production quality and stability may be different. Patients need to purchase them through regular channels to ensure the quality of the drugs.

The medical insurance coverage of lorlatinib improves the accessibility of the drug and provides more treatment possibilities for ALK or ROS1 positive patients. However, patients still need to strictly follow the doctor's instructions during medication, choose appropriate treatment options based on individual conditions, and choose compliant drug sources based on economic conditions. The launch of lorlatinib and the support of medical insurance policies mark the progress of targeted therapy, bringing new hope and longer survival to patients with advanced lung cancer.

xa0

References:

China National Medical Products Administration: https://www.nmpa.gov.cn/